B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

NR1H2

MOLECULAR TARGET

nuclear receptor subfamily 1 group H member 2

UniProt: P55055NCBI Gene: 737616 compounds

NR1H2 (nuclear receptor subfamily 1 group H member 2) is targeted by 16 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting NR1H2

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1t0913174.4786
2ruxolitinib4.2368
3alitretinoin4.0355
4bexarotene4.0355
522r hydroxycholesterol2.7715
6e guggulsterone2.4010
7cyanidin2.4010
8butylparaben2.087
9lxr 6231.956
1024s25 epoxycholesterol1.956
11Desmosterol1.102
12Luteolin 5,7,3',4'-tetrahydroxy-flavone,0.691
13Progesterone0.691
14Gemfibrozil0.691
15bdb 3 4s 4ar 6 hydroxy 4a methyl 1 s methyl 1 2 3 4 4a 9 10 10a octahydro phenanthre0.691
16bdb 4s 4ar 6 hydroxy 4a methyl 1 s methyl 1 2 3 4 4a 9 10 10a octahydro phenanthrene0.691

About NR1H2 as a Drug Target

NR1H2 (nuclear receptor subfamily 1 group H member 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 16 compounds with documented NR1H2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

NR1H2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.